RVL Pharmaceuticals plc announced that it has entered into agreement for a private placement of 15,451,612 shares at an issue price of $1.55 per share for gross proceeds of $23,949,999 on August 4, 2022. The transaction will include participation from new investor Athyrium Opportunities IV Co-Invest 2 LP for 6,451,612 shares, returning investor Avista Healthcare Partners, L.P., a fund managed by Avista Capital Holdings, L.P. for 8,000,000 shares, individual investors director and Chief Executive Officer of the Company Brian Markison for 850,000 shares and Executive Vice President and Chief Operating Officer of the Company James Schaub for 150,000. The transaction is expected to close on August 8, 2022.